SG10201811365RA - Slow-release conjugates of sn-38 - Google Patents

Slow-release conjugates of sn-38

Info

Publication number
SG10201811365RA
SG10201811365RA SG10201811365RA SG10201811365RA SG10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA
Authority
SG
Singapore
Prior art keywords
slow
conjugates
release
release conjugates
glucuronate
Prior art date
Application number
SG10201811365RA
Other languages
English (en)
Inventor
Gary Ashley
Eric L Schneider
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of SG10201811365RA publication Critical patent/SG10201811365RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48Polymers modified by chemical after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
SG10201811365RA 2013-10-04 2014-10-03 Slow-release conjugates of sn-38 SG10201811365RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361887111P 2013-10-04 2013-10-04

Publications (1)

Publication Number Publication Date
SG10201811365RA true SG10201811365RA (en) 2019-02-27

Family

ID=51871275

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201811365RA SG10201811365RA (en) 2013-10-04 2014-10-03 Slow-release conjugates of sn-38
SG11201602258WA SG11201602258WA (en) 2013-10-04 2014-10-03 Slow-release conjugates of sn-38

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201602258WA SG11201602258WA (en) 2013-10-04 2014-10-03 Slow-release conjugates of sn-38

Country Status (14)

Country Link
US (2) US10016411B2 (fr)
EP (1) EP3052101B1 (fr)
JP (2) JP6473145B2 (fr)
KR (1) KR102320753B1 (fr)
CN (1) CN106061483B (fr)
AU (2) AU2014331591B2 (fr)
BR (1) BR112016007410B1 (fr)
CA (1) CA2925132C (fr)
DK (1) DK3052101T3 (fr)
ES (1) ES2759905T3 (fr)
MX (1) MX371201B (fr)
SG (2) SG10201811365RA (fr)
TW (1) TWI716342B (fr)
WO (1) WO2015051307A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6473145B2 (ja) * 2013-10-04 2019-02-20 プロリンクス エルエルシー Sn−38の徐放性コンジュゲート
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药(苏州)股份有限公司 多臂的聚合靶向抗癌偶联物
KR102279429B1 (ko) 2017-04-21 2021-07-20 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. 멀티 암 표적 항암 콘쥬게이트
MX2020007442A (es) 2018-01-12 2020-09-14 Prolynx Llc Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
CA3134838A1 (fr) * 2019-04-05 2020-10-08 Prolynx Llc Lieurs de conjugaison ameliores
EP4021442A4 (fr) * 2019-08-28 2023-09-20 Prolynx LLC Inhibiteurs conjugués de la réponse à l'endommagement de l'adn
CA3193485A1 (fr) 2020-09-28 2022-03-31 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Conjugues peptidiques de sn38 utiles dans le traitement du cancer
WO2023186822A1 (fr) 2022-03-28 2023-10-05 Hospital Sant Joan De Deu Système d'administration peptidique soluble dans l'eau de médicaments anticancéreux

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
JP2005537266A (ja) * 2002-07-12 2005-12-08 バイオマリン ファーマシューティカル インコーポレイテッド 加水分解性活性物質であるバイオポリマーコンジュゲートを作製するためのイソシアネートリンカーの使用
KR101057102B1 (ko) 2002-10-31 2011-08-16 니폰 가야꾸 가부시끼가이샤 캄프토테신의 고분자량 유도체
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
LT1675622T (lt) * 2003-09-17 2017-09-11 Nektar Therapeutics Daugiašakio polimero provaistai
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
AU2007296056B2 (en) * 2006-09-15 2012-09-13 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
BRPI0919842A8 (pt) * 2008-10-21 2015-09-22 Enzon Pharmaceuticals Inc tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecina
AU2009316749A1 (en) 2008-11-18 2011-06-30 Baxter Healthcare S.A. Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
DK2501413T3 (da) * 2009-11-18 2019-06-11 Nektar Therapeutics Syre-saltformer af polymermedikamentkonjugater
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
WO2011140376A1 (fr) * 2010-05-05 2011-11-10 Prolynx Llc Libération contrôlée de médicament à partir de dendrimères
JP2012000072A (ja) * 2010-06-18 2012-01-05 Japan Health Science Foundation 新規な抗フィブリン抗体
AR082806A1 (es) * 2010-08-30 2013-01-09 Sun Pharma Advanced Res Co Ltd Composicion farmaceutica estable
EP2654795B1 (fr) * 2010-12-21 2018-03-07 Nektar Therapeutics Conjugués de prodrogue et polymères à bras multiples à base de pemetrexed
WO2013036857A1 (fr) * 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
JP6473145B2 (ja) * 2013-10-04 2019-02-20 プロリンクス エルエルシー Sn−38の徐放性コンジュゲート

Also Published As

Publication number Publication date
TW201601759A (zh) 2016-01-16
DK3052101T3 (da) 2019-12-16
US20180289695A1 (en) 2018-10-11
BR112016007410B1 (pt) 2022-07-19
MX371201B (es) 2020-01-22
EP3052101A1 (fr) 2016-08-10
AU2014331591A1 (en) 2016-05-19
AU2014331591B2 (en) 2018-08-16
TWI716342B (zh) 2021-01-21
US10342792B2 (en) 2019-07-09
MX2016004299A (es) 2016-10-04
US10016411B2 (en) 2018-07-10
KR20160065203A (ko) 2016-06-08
JP2019104739A (ja) 2019-06-27
WO2015051307A1 (fr) 2015-04-09
BR112016007410A8 (pt) 2020-02-27
CA2925132C (fr) 2021-11-30
JP2016531895A (ja) 2016-10-13
CA2925132A1 (fr) 2015-04-09
KR102320753B1 (ko) 2021-11-02
JP6842479B2 (ja) 2021-03-17
BR112016007410A2 (pt) 2017-08-01
CN106061483A (zh) 2016-10-26
CN106061483B (zh) 2021-01-08
ES2759905T3 (es) 2020-05-12
EP3052101B1 (fr) 2019-11-20
US20160243106A1 (en) 2016-08-25
AU2018256608A1 (en) 2018-11-22
JP6473145B2 (ja) 2019-02-20
SG11201602258WA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
SG10201811365RA (en) Slow-release conjugates of sn-38
EP3065808A4 (fr) Dispositifs et procédés pour l'administration de médicament continue par la bouche
IL278183A (en) Proton-binding polymers for oral administration
MY170719A (en) Antibody-drug conjugates
EP2968753A4 (fr) Introducteur angulaire pour l'infusion de médicament
HK1214819A1 (zh) 二環 -苯並二氮雜䓬和螺環取代的 -苯並二氮雜䓬
EP3077006A4 (fr) Conjugués polymères-hydrates de carbone pour technologie d'administration pharmacologique
IL263965A (en) Cleavable drug polymer conjugates
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
WO2014169007A3 (fr) Combinaison de nanoparticules thérapeutiques
EP3161489A4 (fr) Marqueurs et indicateurs thérapeutiques pour le glioblastome multiforme (gbm)
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
IL269028A (en) Boronized multifunctional drug-targeting conjugates, their uses and methods of preparation
EP2952217A4 (fr) Flacon de céfotoxine médicinale, et appareil de distribution et appareil d'injection associé
IN2013MU02015A (fr)
IN2013MU01226A (fr)
UA84204U (ru) Способ иммунокоррекции больных ветряной оспой с наличием иммунодефицитных состояний
UA92247U (ru) ПРИМЕНЕНИЕ МЕТИЛОВОГО ЭСТЕРА 5-МЕТИЛ-4-ОКСО-3,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИН-6-КАРБОНОВОЙ КИСЛОТЫ КАК АНАЛЬГЕТИЧЕСКОГО И ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА
IN2013MU03310A (fr)
UA99990U (ru) 2-амино-4-метил-9-(2,5-диметоксифенил)-7-оксо-3-циано-6,7,8,9-тетрагидропиридо[3',2':4,5]тиено[3,2-b]пиридин
IN2013MU03468A (fr)
AU2013900230A0 (en) Medicament delivery device for piercings